News in brief: TGA approves Trikafta for CF; Deprescribing ineffective treatments for kids with bronchiolitis; Pembrolizumab promising in mesothelioma

CFTR modulator registered by the TGA Trikafta has been registered by the TGA for the treatment of cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The TGA approval of Trikafta (elexacaftor, ivacaftor, tezacaftor fixed dose combination tablets + ...

Already a member?

Login to keep reading.

© 2021 the limbic